Paratek Pharmaceuticals Inc (NASDAQ:PRTK) COO Evan Loh sold 12,000 shares of the stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $9.97, for a total value of $119,640.00. Following the sale, the chief operating officer now owns 202,786 shares in the company, valued at approximately $2,021,776.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Evan Loh also recently made the following trade(s):
Get Paratek Pharmaceuticals alerts: On Monday, April 9th, Evan Loh sold 8,084 shares of Paratek Pharmaceuticals stock. The stock was sold at an average price of $12.70, for a total value of $102,666.80.Paratek Pharmaceuticals stock opened at $10.55 on Friday. Paratek Pharmaceuticals Inc has a fifty-two week low of $9.85 and a fifty-two week high of $29.00. The company has a debt-to-equity ratio of 0.47, a quick ratio of 8.06 and a current ratio of 8.06.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.03. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. equities analysts anticipate that Paratek Pharmaceuticals Inc will post -3.68 earnings per share for the current fiscal year.
Several equities research analysts have issued reports on the company. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, April 5th. BidaskClub raised shares of Paratek Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Paratek Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $40.00.
Several institutional investors have recently added to or reduced their stakes in PRTK. Highland Capital Management LP increased its holdings in shares of Paratek Pharmaceuticals by 320.9% in the first quarter. Highland Capital Management LP now owns 959,278 shares of the specialty pharmaceutical company’s stock worth $12,471,000 after purchasing an additional 731,378 shares during the period. Omni Partners LLP bought a new position in shares of Paratek Pharmaceuticals in the first quarter worth $2,009,000. BlackRock Inc. increased its stake in Paratek Pharmaceuticals by 6.6% in the first quarter. BlackRock Inc. now owns 2,028,845 shares of the specialty pharmaceutical company’s stock valued at $26,374,000 after acquiring an additional 125,194 shares during the last quarter. California Public Employees Retirement System bought a new position in Paratek Pharmaceuticals in the first quarter valued at $1,565,000. Finally, Renaissance Technologies LLC increased its stake in Paratek Pharmaceuticals by 21.6% in the fourth quarter. Renaissance Technologies LLC now owns 450,649 shares of the specialty pharmaceutical company’s stock valued at $8,067,000 after acquiring an additional 79,911 shares during the last quarter. 77.22% of the stock is currently owned by hedge funds and other institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
No comments:
Post a Comment